Meeting
2019 ASCO Annual Meeting
A phase I, open label, multicenter dose escalation study of AZD2811 nanoparticle in patients with advanced solid tumors.
Authors
Melissa Lynne Johnson
Sarah Cannon Research Institute, Nashville, TN
Melissa Lynne Johnson , Jan G. C. E. Cosaert , Gerald Steven Falchook , Suzanne Fields Jones , Donald Strickland , Carol Greenlees , Julie Charlton , Alexander MacDonald , Philip Overend , Carrie Adelman , Howard A. Burris III, Elizabeth J. Pease , Gargi Surendra Patel , Judy Sing-Zan Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Clinical Trial Registration Number
NCT02579226
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3098)
DOI
10.1200/JCO.2019.37.15_suppl.3098
Abstract #
3098
Poster Bd #
90
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A phase I, open-label, multicenter dose escalation study to assess the safety, tolerability, and pharmacokinetics of AZD2811 nanoparticle in patients with advanced solid tumors.
First Author: Melissa Lynne Johnson
Poster
2018 ASCO Annual Meeting
Vorolanib (CM082) in Chinese patients with advanced solid tumor: A phase 1, open-label, dose escalation study.
First Author: Yan Song
Poster
2017 ASCO Annual Meeting
A phase I dose escalation study of SCB01A, a micro-tubular inhibitor with vascular disrupting activity, in patients with advanced solid tumors refractory to standard therapy.
First Author: Nai-Jung Chiang
Poster
2012 ASCO Annual Meeting
First-in-human study of AMG 900, an oral pan-Aurora kinase inhibitor, in adult patients (pts) with advanced solid tumors.
First Author: Michael Anthony Carducci